
Alastair Peter Greystoke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1996884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563.	0.8	788
2	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 525-532.	0.8	755
3	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine, 2014, 20, 897-903.	15.2	608
4	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816.	1.9	223
5	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment, 2010, 120, 461-467.	1.1	191
6	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	0.5	144
7	Update on tubulin-binding agents. Pathologie Et Biologie, 2006, 54, 72-84.	2.2	134
8	Biomarker method validation in anticancer drug development. British Journal of Pharmacology, 2008, 153, 646-656.	2.7	114
9	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British Journal of Cancer, 2011, 104, 750-755.	2.9	113
10	Biomarkers of apoptosis. British Journal of Cancer, 2008, 99, 841-846.	2.9	101
11	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	3.2	101
12	The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020, 583, 807-812.	13.7	96
13	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 98-107.	1.8	90
14	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. Journal of Thoracic Oncology, 2020, 15, 637-648.	0.5	83
15	Optimisation of circulating biomarkers of cell death for routine clinical use. Annals of Oncology, 2008, 19, 990-995.	0.6	68
16	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer, 2019, 120, 975-981.	2.9	61
17	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer, 2011, 104, 719-725.	2.9	48
18	Alternative splicing in lung cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 194388.	0.9	47

#	Article	IF	CITATIONS
19	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‧mall ell Lung Cancer and in Healthy Volunteers. Journal of Clinical Pharmacology, 2018, 58, 474-484.	1.0	41
20	Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Journal of Medical Economics, 2018, 21, 113-121.	1.0	30
21	A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drug Investigation, 2012, 32, 179-187.	1.1	25
22	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncology, The, 2022, 23, 540-552.	5.1	25
23	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 6284-6294.	3.2	24
24	Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. British Journal of Cancer, 2004, 91, 1651-1655.	2.9	23
25	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology, 2016, 10, 282-291.	2.1	18
26	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. British Journal of Cancer, 2017, 117, 938-946.	2.9	18
27	Biomarkers of cell death applicable to early clinical trials. Experimental Cell Research, 2012, 318, 1252-1259.	1.2	17
28	Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. Ecancermedicalscience, 2015, 9, 594.	0.6	17
29	Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer, 2017, 111, 51-58.	0.9	15
30	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted Oncology, 2022, 17, 153-166.	1.7	15
31	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 2020, 123, 1360-1369.	2.9	10
32	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 2016, 68, 1-10.	1.3	9
33	A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma Journal of Clinical Oncology, 2021, 39, 8558-8558.	0.8	7
34	A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors Journal of Clinical Oncology, 2015, 33, 2593-2593.	0.8	7
35	Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British Journal of Cancer, 2022, 126, 1157-1167.	2.9	7
36	The use of circulating biomarkers in early clinical trials in patients with cancer. Biomarkers in Medicine, 2015, 9, 1011-1023.	0.6	2

#	Article	IF	CITATIONS
37	An introduction to stratified medicine. Drug Discovery Today, 2015, 20, 1409-1413.	3.2	2
38	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON) Journal of Clinical Oncology, 2021, 39, TPS9138-TPS9138.	0.8	2
39	TARGET National: A U.Kwide liquid-based molecular profiling program to enhance recruitment to early-phase trials Journal of Clinical Oncology, 2022, 40, TPS3163-TPS3163.	0.8	2
40	Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?. Radiotherapy and Oncology, 2021, 154, e13.	0.3	1
41	P-OGC20 Can prehabilitation prevent development of sarcopenia during neoadjuvant chemotherapy for oesophagogastric adenocarcinoma?. British Journal of Surgery, 2021, 108, .	0.1	1
42	Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy Journal of Clinical Oncology, 2022, 40, 8560-8560.	0.8	1
43	Serum biomarkers of apoptosis. European Journal of Cancer, Supplement, 2007, 5, 115-127.	2.2	0
44	Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer. Ecancermedicalscience, 2020, 14, 1019.	0.6	0
45	Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Oncology, 2022, , .	0.6	0